TDR Top 5 Developments For The Week in Psychedelics

Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of June 5. Aside from presenting a synopsis of events, we provide market commentary to summarize the week that was for publicly-listed companies.

5.?Drew Barrymore Considering Psychedelics To Explore Why She’s Not Open To Relationship

I’m curious to examine why I’m not open to a relationship. I really think I have some serious shit buried. And I don’t know if it’s like I need to try an?MDMA?treatment or?psilocybin?as a way to get to some state where I could see things in a different way.

Hollywood actress, Drew Barrymore

4.?Rhode Island Advances Psilocybin Reform With Bill To Legalize Therapeutic Access And Cultivation

Rhode Island?is making progress in the area of psychedelics reform as lawmakers approved a bill that could legalize?psilocybin mushrooms. The legislation, introduced by?Rep. Brandon Potter?(D)?received a favorable vote of 12-2 from the House Judiciary Committee,?reported?Marijuana Moment.

If enacted, the bill would decriminalize the possession and cultivation of up to one ounce of psilocybin for personal use. Individuals would be allowed to share this amount with other adults, starting July 1.

The bill?also includes?a provision that hinges on federal action, noted MM. If the federal Food and Drug Administration (FDA) reschedules psilocybin, the Rhode Island Department of Health would be tasked with establishing regulations pertaining to cultivation, distribution, and medical prescription.

__________

Numinus Presents: Psychedelic Therapy Frontiers podcast Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Dan Karlin

__________

3. Psychedelic Stocks Edge Higher Inline With Market And Peers

The psychedelic sector rose slightly this past week, as reflected by the?Advisorshares Psychedelics ETF (PSIL)?↑0.64%. The performance was inline with biopharma peers indices such as the?Nasdaq Junior Biotechnology Index?↑1.02%?and?Nasdaq Biotechnology Ishares ETF↓0.10%. The?NASDAQ 100?↓0.06%?and?S&P 500?↑0.39%were mixed in front of key CPI data expected next Tuesday morning.

Here’s how the Health Care (Biotechnology) sector performed:

In The News…

Alkemist Labs?is gearing up?to handle the increasing interest in psychedelic ingredients. With new laws sanctioning their use and discussions around therapeutic applications, a new market is dawning.

Apex Labs?has secured?Health Canada’s endorsement for its secondary US-based supplier of psilocybin Active Pharmaceutical Ingredient (API).

Awakn Life Sciences?announced?its intention to exit healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of its intellectual property.

Braxia Scientific?reported?treatment volumes across its clinics increased 26.2% to 3,516 from 2,785 treatments on a year-over-year basis in Fiscal 2023.

Colorado Governor?Jared Polis?will present opening remarks?at this year’s?Psychedelics Science 2023?conference, taking place June 19-23, 2023 in Denver, Colorado.

COMPASS Pathways?announced?that the?US Patent Trial and Appeal Board?reaffirmed decisions to uphold ‘257 Patent and ‘259 Patent, key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used in the Company’s phase 3 clinical trials.

Creso Pharma?has signed?a Letter of Intent with Apotheke Dr. Hysek AG, a Swiss pharmacy, for the exclusive import and distribution of licensed MDMA and psilocybin products into Australia

Cybin?Inc.?provides a corporate update?outlining access to capital and upcoming clinical milestones.

Emyria Ltd?has received?Human Research Ethics Committee?(HREC) approval to conduct its ground-breaking MDMA-assisted clinical therapy for patients with Post-Traumatic Stress Disorder.

Energia Foundation, organizer of the?same conversation?within this January’s WEF-parallel Davos House of Health,?is taking education?on the new therapeutics to the Arab world.?

Healing Commercial Real Estate?announced?the addition of esteemed individuals to its board of directors, its advisory board and its participation in the highly anticipated MAPS?Psychedelic Science Conference.

Institute of Biomedical Research Corp.?provided a comprehensive update?on their recent accomplishments and integration of artificial intelligence (AI) in their biotechnology and medical solutions.

Lobe Sciences?announced the appointment?of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately.

Meme Of The Week

Mind Cure Health?announced?that in connection with the Corporation’s previously announced reverse takeover transaction with LNG Energy Group Inc., LNG the initial tranche of a private placement of 31,229,630 subscription receipts of LNG Energy at a price of?$0.50?per Subscription Receipt.

Mike Tyson?takes magic mushrooms every day?and assures psychedelics helped him lose 100 pounds in 4 months.

PharmAla Biotech Holdings?reports?that the US Food and Drug Administration has approved a clinical trial utilizing PharmAla’s LaNeo MDMA Investigational Medical Product (IMP) capsules (40mg).?

Rolland Griffiths?(Dr.) speaks with Oprah…

Psychedelics?induce neuroplasticity resembling the effects of clinically approved antidepressants…

Tampa?biotech company?hopes to be on the verge?of a?mental health?breakthrough with its research into psychedelic drugs.?Psilera?is working to develop non-hallucinogenic medications that can be used to treat a wide range of mental health disorders.?

Young adults?ages 19 to 30 nearly doubled?their past 12-month use of non-LSD hallucinogens in the United States from 2018 to 2021, according to a study by the University of Michigan and Columbia University.

2.?Psilocybin Treatment Helped Patients Process Emotions Related To Painful Past Events

Psilocybin, the active compound found in magic mushrooms, has shown promise in treating various addictions, as indicated by several previous studies. Case in point—a recent scientific inquiry set out to explore a distinct question: how does this psychedelic substance function in addressing alcohol addiction?

A collaborative effort involving researchers from the?University of New York, the University of California, San Francisco, and professionals from the?Fluence?mental health training center?sought to examine the underlying mechanisms?that led individuals with alcohol use disorders to significantly reduce negative drinking behaviors following their participation in a previous psilocybin clinical study.

The study, published in the?Psychology of Addictive Behaviors?and edited by the?American Psychological Association, involved 13 volunteers who had received treatment with psilocybin. Subsequently, researchers reached out to these participants to conduct in-depth qualitative interviews, aiming to gain insights into their experiences during and after the treatment process.

1.?Senator John Fetterman Touts Psilocybin Mushrooms As Mental Health ‘Revolution’ That Could Boost The Economy

Sen. John Fetterman (D-PA) says that psilocybin mushrooms could represent a “revolution” in mental health treatment and an economic “boon” for his home state of Pennsylvania, which he referred to as the “mushroom capital of the world.”

At a Senate Agriculture subcommittee hearing he chaired on Wednesday, the senator said that he’s “been an advocate of psychedelics in terms of magic mushrooms for PTSD and for veterans especially.”

Fetterman, who formerly served as lieutenant governor of Pennsylvania and?strongly advocated for marijuana legalization, has previously said that the country should “open up research into psilocybin.”